New drugs and experimental approaches in ovarian cancer treatment.
D006585:Altretamine / Q000627:therapeutic use; D000609:Aminoacridines / Q000627:therapeutic use; D000677:Amsacrine; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001388:Aziridines / Q000627:therapeutic use; D016227:Benzoquinones; D002066:Busulfan / Q000031:analogs & derivatives / Q000627:therapeutic use; D016190:Carboplatin; D002945:Cisplatin / Q000627:therapeutic use; D004965:Estrogen Antagonists / Q000627:therapeutic use; D005260:Female; D004376:Galactitol / Q000627:therapeutic use; D006801:Humans; D007069:Ifosfamide / Q000627:therapeutic use; D008937:Mitomycins / Q000627:therapeutic use; D009944:Organoplatinum Compounds / Q000627:therapeutic use; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D011238:Prednimustine / Q000627:therapeutic use; D011372:Progestins / Q000627:therapeutic use
D000609:Aminoacridines; D000970:Antineoplastic Agents; D001388:Aziridines; D016227:Benzoquinones; D004965:Estrogen Antagonists; D008937:Mitomycins; D009944:Organoplatinum Compounds; D011372:Progestins; D000677:Amsacrine; D004376:Galactitol; C023359:iproplatin; D011238:Prednimustine; D016190:Carboplatin; C018404:treosulfan; C029108:diaziquone; D002066:Busulfan; D002945:Cisplatin; D006585:Altretamine; D007069:Ifosfamide